Interested in speaking? Apply Here!


MAIN CONFERENCE, DAY ONE | Tuesday, September 25, 2018
Main Conference Registration and Continental Breakfast
Chairperson's Opening Remarks
Keynote Session Enforcement Viewpoints and Priorities for the U.S. Department of Justice
  • Understand the principles that govern the Department of Justice’s enforcement decisions
  • Examine current areas of enforcement priority for the Department of Justice under the Food, Drug, and Cosmetic Act and the False Claims Act
  • Learn about the implications for life sciences companies of the “Brand Memo,” which addresses the use of guidance documents in affirmative civil enforcement cases, and the “Granston Memo,” which addresses government-initiated dismissals of False Claims Act qui tam suits
James M. Burnham, Civil Division, Consumer Protection Branch, U.S. DEPARTMENT OF JUSTICE
Panel Discussion Explore Different Operating Models for Medical Affairs Groups and Discuss How Organizational Structure Can Impact the Effectiveness of Your Activities
  • Review some traditional and innovative operating models for medical affairs across big pharmaceutical and biotech companies
  • Highlight different groups and areas of focus that can be impacted based on the reporting and budgetary structure for a medical affairs group
  • Discuss the difference between expectations and challenges faced by medical and cross-functional leadership and how that can affect a team’s ability to do their job well

Jeymi Tambiah, M.D., Senior Vice President, Medical Affairs, SAMUMED LLC
Radhika Tripuraneni, M.D., Vice President, Medical Affairs, PROTHENA BIOSCIENCES

Leveraging Online Discussion Platforms for Optimal Stakeholder Engagement
  • Identify the logistical and resource barriers to domestic and global stakeholder engagement
  • Learn about innovative communication solutions that leading organizations utilize to overcome these challenges
  • Discuss how to use these solutions to deliver improved engagement outcomes while maintaining regulatory compliance
Lance Hill, CEO, WITHIN3
Networking Break
TRACKED SESSIONS BEGIN | Tuesday, September 25, 2018
Track Chair Opening Remarks
Scott Siegert, Pharm.D., MBA, Executive Director, Head of Medical Affairs, NEUROCRINE BIOSCIENCES
Track Chair Opening Remarks
David Bruhn, Pharm.D., MBA, Director, Health Outcomes Liaisons – Government, Medical Policy and Payers, US Medical Affairs, GSK
How to Survive an Acquisition — A Medical Affairs Perspective
  • Review the different kinds of scenarios that require you to partner with another organization
  • Analyze the impact of this arrangement on the development and execution of medical activities
  • Determine what sort of arrangement best serves your business needs
  • Hear case examples and shared learnings from real-world scenarios from experiences
Elizabeth Faust, Ph.D., Vice President, Medical Affairs, KITE PHARMA
Create and Implement On-Boarding and Training Processes in Biotech/ Pharmaceutical Medical Affairs Departments
  • Collaborate with leadership across medical affairs (U.S. and Global) to understand current processes and/or existing resources
  • Develop an on-boarding agenda to ensure critical start-up skills are completed and crosscollaborative relationships are initiated
  • Incorporate training objectives in medical affairs goals/performance expectations to create a pool of peers across medical affairs that participate and lead training units
  • Assign mentors with clear outlined responsibilities
  • Create processes to provide evidence that initial training is complete and knowledge has been assessed
Christine Chatas, Director, Medical Liaisons, ALEXION
Give the Patient Voice a Seat at the Table
  • Examine concerns patients have expressed regarding historical drug development processes
  • Explain Amicus Therapeutics’ mission and achievements in becoming recognized as a patient-focused company
  • Share real-world examples of ways patients and patient advocacy organizations have shaped Amicus’ novel drug development and commercialization programs
  • Learn how best to become a patient-centric company
Mark Lyles, M.D., MBA, Executive Director, Medical Affairs Strategy, AMICUS THERAPEUTICS
Compliant Interactions Between Medical Affairs and Commercial Colleagues
  • Understand how medical affairs and commercial can collaborate with respect to broad company and product strategies, while maintaining independence and scientific/medical integrity when exercising professional judgment and making decisions
  • Develop actions and behaviors to help ensure compliance with related company policies, external laws and regulations, and industry standards and guidelines
  • Learn how medical affairs work in alignment with commercial personnel to provide non-promotional, scientific and medical support to other cross-functional teams within an organization
Ayman R. Kafal, Ph.D., MBA, Associate Director, Specialty Field Team, Medical Affairs, CSL BEHRING
Take a Patient-Centric Approach to Medical Affairs Engagement
  • Improve outreach with detailed, multifaceted profiling that quickly identifies the right influencers and patient populations for your medical engagement.
  • Optimize scientific engagements with real-time, online predictive data as well as offline analytics support to radically improved results at significantly greater speed.
  • Deliver field-level intelligence on competitor engagements to help you prioritize and compliantly improve the impact of outreach efforts
Stakeholder Interests in Value Discussions Drive the Need for Better Field Medical Coordination
  • Understand how the value discussion has evolved over time as a requirement by external stakeholders and learn the impact that both clinical and economic information can have for KOLs, payers, and healthcare systems
  • Identify the most impactful outcomes data and resources used by value-based health decision makers to make informed decisions
  • Discuss the different models that Field Medical Organizations leverage to address the value discussion externally and the value of coordinating field efforts between MSLs and Field HEOR/Managed Care Liaisons
Christian Dimaano, Ph.D., MPH, National Director, Oncology MSLs, Medical Affairs, Americas, ASTELLAS PHARMA
Julie Greely, Pharm.D., Senior Director, Field Excellence and HEOR, Medical Affairs, Americas, ASTELLAS PHARMA INC
Panel: How to Set Up Compliance Firewalls That Balance SOPs With Practical Needs
  • Review the history of events that have lead companies to develop the compliance framework they have today
  • Understand the origins, what has guided this framework and gain an overview of the legal perspective
  • Learn how to work collaboratively, semi-autonomously or purely independently of other departments based on the culture at your organization
Daniel Snyder, Ph.D., Head, Medical Affairs, Therapeutics, REVANCE THERAPEUTICS, INC.
How to Establish Your Medical Organization Prior to a Commercial Launch
  • Identify key leverage points to ensure successful market access
  • Establish and prepare your field medical team strategically
  • Put in place the right measures to demonstrate value and deliver on the promise
Julie Baron, Ph.D., Director, Field Medical Effectiveness, SHIRE
Networking Break
Effective Use of Mobile Microlearning for Point-of-Need Training: How One Fortune 50 BioPharma is Applying Technology for Increased Clinical Competency
  • Determine how the cloud can precipitate more knowledgeable KOL interactions
  • Hear what happens when clinical data meets Google on YouTube
  • Learn how medical affairs/clinical operations teams can move towards continuous learning
Philip Bedrin, Director of Sales, North America, SCIENCEMEDIA, INC.
Maximize the Value of a Product Nearing the End of Its Patent Through Lifecycle Management
  • Discuss how to keep generating science throughout a product's life cycle
  • Sustain thought leader relationships beyond the life cycle
  • Examine steps to retain market interest and engagement as patent expiration approaches
Sheila Komara, Ph.Dc., RN, Senior Medical Science Liaison, MALLINCKRODT
Cocktail Reception
Day One Concludes
TRACKED SESSIONS DAY TWO | Wednesday, September 26, 2018
Continental Breakfast
Track Chair Recap of Day One
Scott Siegert, Pharm.D., MBA, Executive Director, Head of Medical Affairs, NEUROCRINE BIOSCIENCES
Track Chair Recap of Day One
David Bruhn, Pharm.D., MBA, Director, Health Outcomes Liaisons – Government, Medical Policy and Payers, US Medical Affairs, GSK
Successfully Operationalizing a Franchise-Level Scientific Communication Platform
  • Develop a franchise-level scientific communication platform (SCP) to achieve broad alignment on external communications supporting products, leverage strengths and opportunities, and optimize differentiation in a competitive landscape
  • Create a tool for its dissemination for use by a cross-functional team and gain alignment on highest-priority goals for scientific communications, including scientific pillars and key stakeholders
  • Discuss the benefits of an interactive tool that provides easy access to key information including franchise objectives, key communication points, and recommended counterpoints
  • Identify outstanding data needs that may drive future research directions to support communication goals and broader commercial goals
Tricia L. Gooljarsingh, Senior Director, Medical and Scientific Affairs, IRONWOOD PHARMACEUTICALS
Use Data Mining Techniques to Enhance Customer Engagement
  • Explore different avenues and technologies that can allow MSL teams to profile and segment customer channels to support customer engagement
  • Leverage external databases to identify discrepancies across therapeutic areas and extrapolate data for medical affairs needs
  • Use these insights to develop enhanced resources for MSLs to engage their customer base
If you are interested in leading this session, please contact Michael Williams at
Harness the Power of Technology and Data to Take Medical Affairs to the Next Level
  • Consider how medical affairs is the hub of today's quality- and patient-centric healthcare system, responsible for educating and communicating with all healthcare stakeholders
  • Personalize education and communications to recipient‘s needs, preferences, and biases, in order to be most effective at changing behavior
  • Take an interactive look at the impact of personalization on quality healthcare
Katie Anders, Head of Medical Affairs Strategic Solutions (MASS), MEDSCAPE EDUCATION
Panel: Develop a Streamlined Process for Gathering Clinical and Field Insights and Translate That Data Internally to Shape Medical Strategy
  • Discuss some of the challenges of leveraging CRMs to extract field insights in an intuitive manner
  • Review the different types of intelligence collected
  • Develop a process to collect field intelligence, tier it based on importance/urgency, and report it up the management chain accordingly
  • Use this process as a metric that tracks the frequency and quality of the feedback reported by team members
Lynn Bass, Director, Medical Science Liaisons (Americas), SANTEN
Cristina Costantino, Ph.D., MBA, Senior Scientific Communications Director, GENENTECH
Networking Break
Best Practice in Fair Market Value Assessments for IIT Grants
  • Explore the pressures to ensure grants are defendable, transparent, and represents Fair Market Value (FMV) – Review the different ways companies are organized to assessing IIT grants FMV
  • Examine best practices, common pitfalls, and aspirations
Ying Jiang, Director, Customer Success, IQVIA
Cost-Effective Tactics for Bringing Awareness and Medical Education to a Specific Disease State
  • Identify well published and influential healthcare professionals that would be interested in training the next generation of KOLs/thought leaders
  • Establish common goals and processes for these seasoned veterans to mentor these young physicians
  • Consider the benefits of publishing open access papers online
Duke Dickerson, Ph.D., M.Sc., MBA, Regional Medical Director, Orphan and Rare Diseases, HORIZON PHARMA
Panel: When Will This Be Published? — Develop an Effective Medical Communications Strategy to Ensure Timely Dissemination of Disease Background and Drug Product Information
  • Draft a compelling publication plan in a dynamic environment
  • Optimize journal selection to reduce time from publication development to publishing
  • Utilize social media to improve the depth and breadth of target audience reach

Colville Brown, M.D., Executive Medical Director, INNOCOLL PHARMACEUTICALS
Elizabeth L. Pham, Senior Director, Global Publications, HALOZYME THERAPEUTICS

Medical Affairs and Patient Advocacy – Where Do They Meet?
  • Gain an overview of the overall global strategy to roll out patient-centric programs
  • Identify opportunities to partner with patient advocacy groups and determine who is the best partner for your company
  • Leverage these partnerships to understand what is best for the patient and don’t miss the opportunity to measure endpoints and outcomes important to key external stakeholders
  • Work with compliance partners to create innovative patient-centric programs
  • Measure the performance and success of patient centricity
Heather S. Ambrose, Director, Acute Care Field Medical and Patient Advocacy, BTG INTERNATIONAL
Understand the Purpose of an Investigator-Initiated Trial From the Company Perspective
  • Hear some of the strategic reasons why companies can benefit for investigator-initiated research
  • Understand common pitfalls and challenges when managing IITs
  • Discover best practices for optimizing the life cycle of an IIT
Bruce M. Schechter, Pharm.D., CMPP,, Director, Scientific Communications, Rheumatology Therapeutic Area Lead, Medical Scientific Affairs Operations, IRONWOOD PHARMACEUTICALS
Weigh the Benefits of Establishing an MSL Rotational Program
  • Highlight some of the obstacles field medical faces in gaining experience and exposure within the organization
  • Identify opportunities and establish a framework for a MSL rotational program with buy-in from executive leadership
  • Gain an overview of the rotational program and discuss key insights
Kunal Ramani, Pharm.D., Senior Medical Science Liaison, STRONGBRIDGE BIOPHARMA
Track Chair Closing Remarks
Scott Siegert, Pharm.D., MBA, Executive Director, Head of Medical Affairs, NEUROCRINE BIOSCIENCES
Track Chair Closing Remarks
David Bruhn, Pharm.D., MBA, Director, Health Outcomes Liaisons – Government, Medical Policy and Payers, US Medical Affairs, GSK
Conference Concludes

Conference Documentation

Request Event Documentation Conference Documentation
live chat software